The FDA approval of amivantamab and lazertinib transforms frontline treatment for EGFR-mutated lung cancer, enhancing patient outcomes and convenience.
Alexander I. Spira, MD, PhD, FACP, FASCO
Advertisement
Articles by Alexander I. Spira, MD, PhD, FACP, FASCO
Experts explore the evolving standards of care for EGFR-mutated advanced NSCLC, highlighting therapy selection and innovative combination strategies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5